Get the Stockscreener App
84.73
1.11%
0.93
After Hours:
85.89
1.16
+1.37%
Incyte Corp stock is traded at $84.73, with a volume of 949.56K.
It is up +1.11% in the last 24 hours and up +1.96% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$83.80
Open:
$84.39
24h Volume:
949.56K
Relative Volume:
0.56
Market Cap:
$16.55B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
19.26
EPS:
4.3988
Net Cash Flow:
$945.58M
1W Performance:
-2.87%
1M Performance:
+1.96%
6M Performance:
+48.99%
1Y Performance:
+28.15%
1-Day Range:
$82.81
$85.15
1-Week Range:
$82.81
$87.95
52-Week Range:
$53.56
$88.66
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
84.73 | 16.36B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Using Python tools to backtest Incyte Corporation strategiesJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Can Incyte Corporation rally from current levelsQuarterly Risk Review & Daily Price Action Insights - newser.com
Incyte jumps amid takeover speculation - MSN
How Incyte Corporation stock compares to market leadersWeekly Trade Report & Weekly Hot Stock Watchlists - newser.com
Incyte (INCY) Announces Promising Study Results for Cancer Treatments - GuruFocus
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - Yahoo Finance
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock - MarketBeat
RBC Capital Remains a Hold on Incyte (INCY) - The Globe and Mail
What 14 Analyst Ratings Have To Say About Incyte - Benzinga
Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus
Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat
Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat
Is Incyte Corporation stock a safe buy before earnings2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Incyte Faces Revenue Squeeze As Jakafi Patent Winds Down - Finimize
Incyte to Report Third Quarter Financial Results - Business Wire
Incyte stock rating downgraded to Perform by Oppenheimer - Investing.com
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Incyte Corporation (INCY) Appoints New Principal Financial Officer - GuruFocus
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
How to use Fibonacci retracement on Incyte CorporationPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
Grimes & Company Inc. Has $12.26 Million Position in Incyte Corporation $INCY - MarketBeat
Price action breakdown for Incyte CorporationJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Legacy Trust Cuts Holdings in Incyte Corporation $INCY - MarketBeat
Published on: 2025-10-05 05:30:49 - newser.com
Why Incyte Corporation (ICY) stock is favored by hedge funds2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How Incyte Corporation (ICY) stock reacts to stronger dollar2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Institutional scanner results for Incyte Corporation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner - MyChesCo
Incyte Appoints Thomas Tray as Financial Officer - The Globe and Mail
Impact Investors Inc Has $209,000 Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Will Incyte's (INCY) New Strategy Team and CALR Antibody Hopes Reshape Its Long-Term Story? - simplywall.st
Incyte appoints Thomas Tray as principal financial officer - StreetInsider
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Incyte (INCY) Is Up 5.7% After FDA Pediatric Opzelura Approval and Leadership Updates Has the Bull Case Changed? - simplywall.st
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition - MyChesCo
Will Incyte Corporation stock outperform value stocksWeekly Gains Report & Community Consensus Trade Alerts - newser.com
Backtesting results for Incyte Corporation trading strategiesMarket Risk Summary & Community Consensus Picks - newser.com
Incyte Corporation stock hits 52-week high at 88.19 USD By Investing.com - Investing.com Australia
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis - MSN
Incyte Corporation stock hits 52-week high at 88.19 USD - Investing.com
Robeco Institutional Asset Management B.V. Has $162.51 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Hits New 1-Year HighHere's What Happened - MarketBeat
2 Reasons to Like INCY and 1 to Stay Skeptical - The Globe and Mail
Lbp Am Sa Has $12.17 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Public Employees Retirement System of Ohio Buys 3,951 Shares of Incyte Corporation $INCY - MarketBeat
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Will Incyte Corporation (ICY) stock see insider accumulationQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Oct 03 '25 |
Sale |
85.54 |
3,501 |
299,476 |
26,569 |
| Denton Sheila A. | EVP & General Counsel |
Oct 02 '25 |
Sale |
87.65 |
599 |
52,502 |
33,200 |
7.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):